GLP-3R Injection Guide: Safe Step-by-Step Instructions

Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery | Last updated: August 21, 2026

Key Takeaways

• GLP-3R (retatrutide) is an investigational triple-agonist peptide that activates GIP, GLP-1, and glucagon receptors to support significant weight loss and cardiometabolic improvements under medical supervision.¹
• Accurate reconstitution math, correct injection technique, and weekly site rotation are essential for safe self-administration and for reducing the risk of lipohypertrophy.
• Follow the stepwise titration schedule (2 mg → 4 mg → 6 mg → 9 mg → 12 mg) with four-week intervals, and keep a strict seven-day dosing interval without double-dosing after a missed injection.
• Structured monitoring of weight, labs, heart rate, and side effects, especially during dose escalation, supports safety and timely adjustments by your practitioner.
• Patients who want a medically supervised GLP-3R protocol can schedule a consultation at Mirror Plastic Surgery for personalized dosing, ongoing support, and lab-guided care.

Meet Your Practitioner: Ellie Pranckevicius, FNP-BC

Ellie Pranckevicius, FNP-BC, leads peptide therapies at Mirror Plastic Surgery in St. Petersburg, Florida. She is a board-certified Family Nurse Practitioner with degrees from Boston University and the University of South Florida. She spent four years in the Neuroscience ICU at Tampa General Hospital before moving into concierge peptide care. Ellie oversees every GLP-3R protocol at Mirror Plastic Surgery, from initial lab review and reconstitution teaching to dose titration and side-effect monitoring. Her combined background in esthetics and advanced clinical nursing allows her to address both metabolic health and the aesthetic goals patients bring to each visit.

Book an appointment with Ellie for a personalized GLP-3R protocol based on your lab results and health history.

How Retatrutide Works and Where It Stands Today

Retatrutide is a first-in-class GIP/GLP-1/glucagon triple hormone receptor agonist developed by Eli Lilly. Unlike single-agonist GLP-1 medications, retatrutide engages three receptor pathways at once. GIP receptors enhance insulin secretion and fat metabolism. GLP-1 receptors suppress appetite and slow gastric emptying. Glucagon receptors increase hepatic energy expenditure. This triple mechanism helps explain why the 12 mg dose produced a mean 28.3% body weight reduction at 80 weeks in the TRIUMPH-1 Phase 3 trial, with results described as approaching bariatric surgery outcomes.¹ Retatrutide remains an investigational molecule. The FDA has not approved it for any condition as of August 2026, and Eli Lilly plans to submit a Biologics License Application in Q1 2027. This article supports patients already under medical supervision and does not serve as a prescription or clinical recommendation.

Supplies You Need Before Your First Injection

Gather every item on this list before you reconstitute or inject GLP-3R:

1. Retatrutide lyophilized powder vial (10 mg, 15 mg, or 20 mg, as prescribed)
2. Bacteriostatic water for injection (0.9% benzyl alcohol), multi-dose vial
3. Two sterile 1 mL or 3 mL syringes with 18–21 gauge needles for drawing BAC water
4. U-100 insulin syringes (29–31 gauge, 4–6 mm needle length) for subcutaneous injection
5. 70% isopropyl alcohol swabs
6. Sterile gauze pads
7. FDA-cleared sharps disposal container
8. Permanent marker and label tape for vial dating
9. Refrigerator capable of maintaining 2–8°C (35.6–46.4°F)
10. Injection site log (paper or digital)

Quick Reference: 7-Step Injection Checklist

1. Wash hands thoroughly with soap and water for at least 20 seconds.
2. Remove the reconstituted vial from the refrigerator and let it reach room temperature for about 15–20 minutes.
3. Swab the vial stopper with a fresh alcohol swab and let it air-dry completely.
4. Draw the prescribed volume into a U-100 insulin syringe (see reconstitution table below).
5. Select and swab the injection site, then let it air-dry completely before inserting the needle.
6. Pinch a skin fold for lean patients or insert at 90 degrees, depress the plunger slowly and steadily, then hold for 5–10 seconds before withdrawing.
7. Dispose of the needle immediately in the sharps container and log the date, dose, and site used.

Reconstitution Math and Technique for Common Vial Sizes

The reconstitution formula Ellie uses with every patient is simple. Concentration (mg/mL) = Peptide mass (mg) ÷ BAC water volume (mL). To convert a dose to syringe units on a U-100 insulin syringe, use this formula. Units = (Dose in mg ÷ Concentration in mg/mL) × 100. The table below applies these formulas to three common compounded vial sizes. Bacteriostatic water containing 0.9% benzyl alcohol is the preferred diluent because its preservative extends multi-dose shelf life to 28–30 days when refrigerated at 2–8°C.

Vial Size	BAC Water Added	Resulting Concentration	2 mg Dose = Units (U-100)	4 mg Dose = Units (U-100)	9 mg Dose = Units (U-100)
10 mg	2 mL	5 mg/mL	40 units (0.40 mL)	80 units (0.80 mL)	180 units (1.80 mL)*
15 mg	3 mL	5 mg/mL	40 units (0.40 mL)	80 units (0.80 mL)	180 units (1.80 mL)*
20 mg	2 mL	10 mg/mL	20 units (0.20 mL)	40 units (0.40 mL)	90 units (0.90 mL)

*A 9 mg dose from a 10 mg or 15 mg vial at 5 mg/mL requires 1.80 mL, which exceeds a standard 1 mL insulin syringe. Ellie recommends a 3 mL syringe for doses above 8 mg at this concentration or reconstitution to 10 mg/mL to keep volumes manageable. Because retatrutide has no FDA-approved manufacturer reconstitution protocol, confirm all volumes with your supervising practitioner before the first draw.

Reconstitution technique: Inject bacteriostatic water slowly down the inner wall of the vial, not directly onto the lyophilized cake, to reduce foam. Swirl gently for 30–60 seconds until the solution looks clear and colorless. Do not shake. Label the vial with the concentration, reconstitution date, and beyond-use date (28 days). Refrigerate immediately at 2–8°C. Discard the vial if the solution appears cloudy, discolored, or contains particulate matter.

Step-by-Step Subcutaneous Injection and Site Rotation

Once your vial is properly reconstituted and refrigerated, you can prepare for your first injection. Follow the 7-step checklist in the callout above. The guidance below expands on site selection and rotation.

Approved injection sites for GLP receptor agonists, consistent with 2016 Mayo Clinic Proceedings recommendations, include these areas:

1. Abdomen: At least 5 cm (two adult fingerbreadths) from the navel, divided into four quadrants (upper left, upper right, lower left, lower right).
2. Front or outer thigh: Upper third of the anterior lateral aspect, avoiding the inner thigh crease.
3. Posterior lateral buttocks: Middle outer quadrant.
4. Back of upper arm: Middle third posterior aspect, which usually requires assistance or a mirror.

Site rotation pattern (descriptive): An eight-zone weekly rotation cycles through abdomen upper-left, abdomen upper-right, abdomen lower-left, abdomen lower-right, left thigh, right thigh, left upper arm, and right upper arm, then repeats. Place each injection within a zone at least 2.5 cm from the prior month’s mark in that zone. Avoid skin that feels hard, lumpy, or tender, because these signs suggest lipohypertrophy that can impair absorption.

Needle angle: A 4 mm needle inserted at 90 degrees suits most adults regardless of BMI. Lean patients should pinch a skin fold to avoid intramuscular delivery. Do not aspirate before injecting. After withdrawing the needle, apply gentle pressure with sterile gauze and avoid rubbing.

Retatrutide Dosing Schedule and Missed-Dose Rules

TRIUMPH Phase 3 trials used a stepwise titration beginning at 2 mg once weekly, with dose increases every four weeks as tolerated. The schedule below mirrors the protocol used for participants who reached the 12 mg maintenance dose.

Weeks	Dose	Frequency
1–4	2 mg	Once weekly
5–8	4 mg	Once weekly
9–12	6 mg	Once weekly
13–16	9 mg	Once weekly
17+	12 mg (or as prescribed)	Once weekly

Ellie may slow or pause titration if gastrointestinal symptoms interfere with daily function. She makes this decision in consultation with you rather than as a self-directed adjustment.

Missed-dose rules: Modeled on Zepbound labeling, the guidance is clear. If fewer than 4 days have passed since the missed dose, administer it as soon as possible and resume the regular weekly schedule. If more than 4 days have passed, skip the missed dose and resume on the next scheduled day. Never double-dose. Retatrutide follows a fixed weekly day with a roughly seven-day interval, and injecting every 6 days on a consistent basis is not supported by trial protocols and should not be self-initiated.

Side-Effect Monitoring and When to Call Ellie

In TRIUMPH-4 at the 12 mg dose, nausea occurred in 43.2% of participants, vomiting in 26%, and dysesthesia in 20.9%, with events predominantly mild to moderate and most pronounced during dose escalation.¹ Structured monitoring in trials tracks body weight, blood glucose, HbA1c, lipid profile, liver function, renal function, blood pressure, heart rate, and in some protocols calcitonin levels, typically every four weeks during escalation.

Safe Sharps Disposal at Home

Used needles and syringes must go directly into an FDA-cleared sharps disposal container, not into household recycling or trash. The CDC recommends a puncture-resistant, leak-proof container with a tight-fitting lid. When the container reaches the fill line, usually around three-quarters full, seal it and follow your local guidelines for drop-off or mail-back disposal. Never recap a used needle. Ellie provides specific disposal instructions and can direct patients to local collection sites in the St. Petersburg and Tampa Bay area.

Why Medical Supervision Matters With GLP-3R

America’s Poison Centers recorded a 265% increase in human exposures to retatrutide in the first four months of 2026 compared with the last four months of 2025, driven largely by unregulated online sources. Retatrutide sold as a research chemical online is not manufactured or assayed to pharmaceutical standards, so potency, sterility, and identity remain uncertain. USP General Chapter 797 requires sterile compounding of injectables in an ISO Class 5 environment by trained personnel using validated aseptic technique, which home settings cannot provide.

Practical Safety Checklist for GLP-3R Patients

Before your first GLP-3R injection, confirm these safety checkpoints.

• A licensed practitioner has reviewed a baseline lab panel and found no contraindications, including personal or family history of medullary thyroid carcinoma, MEN2, active pancreatitis, or severe GI disease.
• The vial label confirms the peptide name, concentration, lot number, and beyond-use date from a licensed compounding pharmacy.
• Bacteriostatic water, not sterile water, was used for reconstitution.
• The reconstituted solution looks clear, colorless, and free of particulate matter.
• An injection site log is ready and the first zone in the rotation is identified.
• A sharps container sits within arm’s reach of the injection area.

Use these prompts at every follow-up with Ellie.

• Is my current dose producing the expected metabolic response based on my labs?
• Are any GI symptoms significant enough to justify slowing titration?
• Has my heart rate trended upward, and does that change the need for an ECG?
• Are there injection site changes, such as lumps or persistent redness, that suggest lipohypertrophy?

How GLP-3R Fits Into Mirror Plastic Surgery Peptide Plans

GLP-3R functions as one component of a broader concierge peptide menu at Mirror Plastic Surgery. Patients managing weight and systemic inflammation may pair GLP-3R with BPC-157 or TB500 for tissue repair, or with NAD for mitochondrial energy support. Patients addressing skin aging at the same time can explore GHK-CU for collagen and elastin production. Ellie builds each protocol from lab data and health history, so no two stacks are identical. The practice serves patients in St. Petersburg and Tampa Bay in person and remotely across the United States, including Hawaii and Alaska, with the full consultation-to-shipment process available through telemedicine.

Frequently Asked Questions

How do I reconstitute 10 mg of GLP-3R?

Add 2 mL of bacteriostatic water (0.9% benzyl alcohol) to a 10 mg retatrutide vial to produce a 5 mg/mL concentration. Clean the vial stopper with a 70% isopropyl alcohol swab and let it dry. Draw 2 mL of bacteriostatic water into a sterile syringe and inject it slowly down the inner wall of the vial, not directly onto the powder, to minimize foaming. Swirl gently for 30–60 seconds until the solution looks clear and colorless, and do not shake. Label the vial with the concentration (5 mg/mL), reconstitution date, and a beyond-use date 28 days out. Refrigerate immediately at 2–8°C. At 5 mg/mL, a 2 mg dose equals 40 units on a U-100 insulin syringe, a 4 mg dose equals 80 units, and a 9 mg dose equals 180 units, which requires a 3 mL syringe. Confirm all reconstitution volumes with your supervising practitioner before the first draw.

Can I take retatrutide every 6 days?

No. Retatrutide has been studied only as a once-weekly subcutaneous injection anchored to a fixed day of the week, with a roughly seven-day interval between doses. This cadence comes from Phase 2 and Phase 3 TRIUMPH trials and underpins all current safety and efficacy data. Shortening the interval to six days on a consistent basis has not been evaluated and could increase exposure-related side effects, particularly gastrointestinal and cardiovascular, without clear benefit. If scheduling conflicts make a fixed weekly day difficult, discuss an alternative anchor day with Ellie rather than compressing the interval.

What happens if I miss a dose of retatrutide?

If fewer than four days have passed since the missed injection, administer the dose as soon as you remember and then continue your weekly schedule from that new day. If more than four days have passed, skip the missed dose and inject on your next originally scheduled day. Never administer two doses within the same week to make up for a missed one. Missing a single dose rarely affects long-term outcomes, but missing multiple consecutive doses during titration may prompt Ellie to reassess whether the current dose level remains appropriate or whether a step-down is needed to support tolerability when restarting.

What side effects should I expect during dose escalation?

Nausea, diarrhea, constipation, and vomiting occur most often and usually appear during the first few weeks of a new dose level. These effects are generally mild to moderate and tend to improve as your body adapts. Fatigue, dizziness, headache, and mild injection site reactions such as redness, bruising, or small firm nodules can also appear. A modest increase in resting heart rate of about 5–10 beats per minute has been observed in trial participants, often peaking around week 24. Ellie monitors heart rate, blood pressure, and metabolic markers at regular intervals throughout the protocol. Any symptom that feels severe, keeps worsening, or appears with red-flag signs discussed in your visit should prompt immediate contact with Ellie.

Is GLP-3R available without a prescription or medical supervision?

Retatrutide is not FDA-approved as of August 2026 and cannot be legally marketed or distributed in the United States outside clinical trials or licensed compounding under practitioner oversight. Products sold online as “research chemicals” offer no guarantee of identity, potency, or sterility. At Mirror Plastic Surgery, GLP-3R is dispensed only after a comprehensive consultation, baseline lab review, and individualized protocol design by Ellie. Peptides come from compounding pharmacies with documented batch testing, and patients receive ongoing concierge support, including direct text access to Ellie, throughout the protocol.

Summary and Next Steps With Mirror Plastic Surgery

Safe GLP-3R self-administration depends on precise reconstitution math, consistent site rotation, adherence to a once-weekly titration schedule, and structured monitoring by a qualified practitioner. TRIUMPH Phase 3 data show that retatrutide produces clinically meaningful weight loss and cardiometabolic improvements across all studied doses, but those results occurred under rigorous clinical oversight, not unsupervised self-administration from unverified sources.¹ Every element of this guide, from the reconstitution table to the missed-dose rules, supports patients already working within a medically supervised protocol rather than replacing that care.

Ellie Pranckevicius offers video demonstrations of reconstitution and injection technique, ongoing telemedicine check-ins, and 24/7 text support for all active GLP-3R patients at Mirror Plastic Surgery. Book an appointment with Ellie to start with a full lab panel and a protocol designed for your physiology and goals.